vs

Side-by-side financial comparison of PARK OHIO HOLDINGS CORP (PKOH) and Royalty Pharma plc (RPRX). Click either name above to swap in a different company.

Royalty Pharma plc is the larger business by last-quarter revenue ($622.0M vs $395.0M, roughly 1.6× PARK OHIO HOLDINGS CORP). Royalty Pharma plc runs the higher net margin — 34.4% vs 0.3%, a 34.2% gap on every dollar of revenue. On growth, Royalty Pharma plc posted the faster year-over-year revenue change (4.8% vs 1.7%). Over the past eight quarters, Royalty Pharma plc's revenue compounded faster (4.6% CAGR vs -2.7%).

The Park National Bank is the lead bank in the $9.9 billion Park National Corporation serving Ohio, Northern Kentucky, and the Carolinas. The bank has three affiliate financial institutions, including Guardian Finance Company, Scope Aircraft Leasing, and SE Property Holdings, LLC. Park National Bank is headquartered in Newark, Ohio.

Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.

PKOH vs RPRX — Head-to-Head

Bigger by revenue
RPRX
RPRX
1.6× larger
RPRX
$622.0M
$395.0M
PKOH
Growing faster (revenue YoY)
RPRX
RPRX
+3.1% gap
RPRX
4.8%
1.7%
PKOH
Higher net margin
RPRX
RPRX
34.2% more per $
RPRX
34.4%
0.3%
PKOH
Faster 2-yr revenue CAGR
RPRX
RPRX
Annualised
RPRX
4.6%
-2.7%
PKOH

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
PKOH
PKOH
RPRX
RPRX
Revenue
$395.0M
$622.0M
Net Profit
$1.0M
$214.2M
Gross Margin
17.3%
Operating Margin
2.5%
62.4%
Net Margin
0.3%
34.4%
Revenue YoY
1.7%
4.8%
Net Profit YoY
100.0%
2.9%
EPS (diluted)
$0.06
$0.49

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
PKOH
PKOH
RPRX
RPRX
Q4 25
$395.0M
$622.0M
Q3 25
$398.6M
$609.3M
Q2 25
$400.1M
$578.7M
Q1 25
$405.4M
$568.2M
Q4 24
$388.4M
$593.6M
Q3 24
$417.6M
$564.7M
Q2 24
$432.6M
$537.3M
Q1 24
$417.6M
$568.0M
Net Profit
PKOH
PKOH
RPRX
RPRX
Q4 25
$1.0M
$214.2M
Q3 25
$5.3M
$288.2M
Q2 25
$9.2M
$30.2M
Q1 25
$8.3M
$238.3M
Q4 24
$500.0K
$208.2M
Q3 24
$9.8M
$544.0M
Q2 24
$11.9M
$102.0M
Q1 24
$9.6M
$4.8M
Gross Margin
PKOH
PKOH
RPRX
RPRX
Q4 25
17.3%
Q3 25
16.7%
Q2 25
17.0%
Q1 25
16.8%
Q4 24
16.6%
Q3 24
17.3%
Q2 24
16.9%
Q1 24
17.1%
Operating Margin
PKOH
PKOH
RPRX
RPRX
Q4 25
2.5%
62.4%
Q3 25
4.3%
70.1%
Q2 25
5.0%
36.3%
Q1 25
4.7%
94.0%
Q4 24
3.7%
60.9%
Q3 24
5.7%
Q2 24
5.7%
50.2%
Q1 24
5.7%
-13.0%
Net Margin
PKOH
PKOH
RPRX
RPRX
Q4 25
0.3%
34.4%
Q3 25
1.3%
47.3%
Q2 25
2.3%
5.2%
Q1 25
2.0%
41.9%
Q4 24
0.1%
35.1%
Q3 24
2.3%
96.3%
Q2 24
2.8%
19.0%
Q1 24
2.3%
0.8%
EPS (diluted)
PKOH
PKOH
RPRX
RPRX
Q4 25
$0.06
$0.49
Q3 25
$0.38
$0.67
Q2 25
$0.66
$0.07
Q1 25
$0.60
$0.55
Q4 24
$0.00
$0.46
Q3 24
$0.73
$1.21
Q2 24
$0.92
$0.23
Q1 24
$0.75
$0.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
PKOH
PKOH
RPRX
RPRX
Cash + ST InvestmentsLiquidity on hand
$44.8M
$618.7M
Total DebtLower is stronger
$9.0B
Stockholders' EquityBook value
$380.9M
$9.7B
Total Assets
$1.4B
$19.6B
Debt / EquityLower = less leverage
0.92×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
PKOH
PKOH
RPRX
RPRX
Q4 25
$44.8M
$618.7M
Q3 25
$50.8M
$938.9M
Q2 25
$45.6M
$631.9M
Q1 25
$54.5M
$1.1B
Q4 24
$53.1M
$929.0M
Q3 24
$59.5M
$950.1M
Q2 24
$59.9M
$1.8B
Q1 24
$61.6M
$843.0M
Total Debt
PKOH
PKOH
RPRX
RPRX
Q4 25
$9.0B
Q3 25
$8.9B
Q2 25
$8.0B
Q1 25
$7.6B
Q4 24
$7.6B
Q3 24
$7.6B
Q2 24
$7.6B
Q1 24
$6.1B
Stockholders' Equity
PKOH
PKOH
RPRX
RPRX
Q4 25
$380.9M
$9.7B
Q3 25
$374.8M
$9.6B
Q2 25
$371.1M
$9.5B
Q1 25
$349.2M
$9.8B
Q4 24
$330.8M
$10.3B
Q3 24
$335.9M
$10.3B
Q2 24
$293.8M
$9.8B
Q1 24
$288.5M
$9.9B
Total Assets
PKOH
PKOH
RPRX
RPRX
Q4 25
$1.4B
$19.6B
Q3 25
$1.4B
$19.3B
Q2 25
$1.4B
$18.3B
Q1 25
$1.4B
$17.6B
Q4 24
$1.4B
$18.2B
Q3 24
$1.4B
$18.0B
Q2 24
$1.4B
$17.7B
Q1 24
$1.4B
$16.1B
Debt / Equity
PKOH
PKOH
RPRX
RPRX
Q4 25
0.92×
Q3 25
0.93×
Q2 25
0.84×
Q1 25
0.78×
Q4 24
0.74×
Q3 24
0.74×
Q2 24
0.78×
Q1 24
0.62×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
PKOH
PKOH
RPRX
RPRX
Operating Cash FlowLast quarter
$48.7M
$827.1M
Free Cash FlowOCF − Capex
$36.0M
FCF MarginFCF / Revenue
9.1%
Capex IntensityCapex / Revenue
3.2%
Cash ConversionOCF / Net Profit
48.70×
3.86×
TTM Free Cash FlowTrailing 4 quarters
$2.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
PKOH
PKOH
RPRX
RPRX
Q4 25
$48.7M
$827.1M
Q3 25
$17.3M
$702.6M
Q2 25
$-13.7M
$364.0M
Q1 25
$-10.0M
$596.1M
Q4 24
$26.4M
$742.5M
Q3 24
$9.0M
$703.6M
Q2 24
$-2.7M
$658.2M
Q1 24
$2.3M
$664.6M
Free Cash Flow
PKOH
PKOH
RPRX
RPRX
Q4 25
$36.0M
Q3 25
$6.6M
Q2 25
$-21.1M
Q1 25
$-19.5M
Q4 24
$17.3M
Q3 24
$-100.0K
Q2 24
$-10.1M
Q1 24
$-3.5M
FCF Margin
PKOH
PKOH
RPRX
RPRX
Q4 25
9.1%
Q3 25
1.7%
Q2 25
-5.3%
Q1 25
-4.8%
Q4 24
4.5%
Q3 24
-0.0%
Q2 24
-2.3%
Q1 24
-0.8%
Capex Intensity
PKOH
PKOH
RPRX
RPRX
Q4 25
3.2%
Q3 25
2.7%
Q2 25
1.8%
Q1 25
2.3%
Q4 24
2.3%
Q3 24
2.2%
Q2 24
1.7%
Q1 24
1.4%
Cash Conversion
PKOH
PKOH
RPRX
RPRX
Q4 25
48.70×
3.86×
Q3 25
3.26×
2.44×
Q2 25
-1.49×
12.06×
Q1 25
-1.20×
2.50×
Q4 24
52.80×
3.57×
Q3 24
0.92×
1.29×
Q2 24
-0.23×
6.45×
Q1 24
0.24×
139.10×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

PKOH
PKOH

Supply Technologies Product$164.6M42%
Engineered Products$116.3M29%
Fuel Rubber And Plastic Products$91.6M23%
Engineered Specialty Products$22.5M6%

RPRX
RPRX

Financial Royalty Assets$592.4M95%
Royalty Income Other$29.6M5%

Related Comparisons